Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

被引:7
|
作者
Mailankody, Sham [1 ]
Matous, Jeffrey, V [2 ]
Liedtke, Michaela [3 ,4 ]
Sidana, Surbhi [5 ]
Oluwole, Olalekan O. [6 ]
Mohan, Meera [7 ]
Cruz, Jose C. [8 ]
Nath, Rajneesh [9 ]
Anwer, Faiz [10 ]
Rossi, Adriana [11 ]
Htut, Myo [12 ]
Malik, Shahbaz A. [13 ]
Ghatta, Srinivas [14 ]
Dillon, Myles [14 ]
Ying, Wendy [14 ]
Navale, Lynn [14 ]
Karski, Erin E. [14 ]
Balakumaran, Arun [14 ]
Kumar, Shaji K. [15 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Colorado Blood Canc Inst, Denver, CO USA
[3] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
[4] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA
[5] Stanford Univ, Sch Med, Dept Med, Div Blood & Marrow Transplantat & Cellular Therap, Stanford, CA USA
[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[7] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA
[8] Texas Transplant Inst, San Antonio, TX USA
[9] Banner MD Anderson Canc Ctr, Scottsdale, AZ USA
[10] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[11] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA
[12] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA
[13] St Davids South Austin Med Ctr, Austin, TX USA
[14] Allogene Therapeut, South San Francisco, CA USA
[15] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA
关键词
D O I
10.1182/blood-2022-158231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:4620 / 4622
页数:3
相关论文
共 50 条
  • [1] Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
    Mailankody, Sham
    Liedtke, Michaela
    Sidana, Surbhi
    Matous, Jeffrey V.
    Chhabra, Saurabh
    Oluwole, Olalekan O.
    Malik, Shahbaz A.
    Kumar, Shaji
    Nath, Rajneesh
    Anwer, Faiz
    Cruz, Jose Carlos
    Jagannath, Sundar
    Htut, Myo
    Raje, Noopur S.
    Siegel, David S.
    Karski, Erin E.
    Lovelace, Wade
    Lourbakos, Afrodite
    Nandakumar, Srinand Ponnathapura
    Balakumaran, Arun
    Hari, Parameswaran
    BLOOD, 2021, 138
  • [2] Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
    Mailankody, Sham
    Matous, Jeffrey V.
    Liedtke, Michaela
    Sidana, Surbhi
    Malik, Shahbaz
    Nath, Rajneesh
    Oluwole, Olalekan O.
    Karski, Erin E.
    Lovelace, Wade
    Zhou, Xiangdong
    Nandakumar, Srinand
    Balakumaran, Arun
    Hari, Parameswaran
    BLOOD, 2020, 136
  • [3] ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
    Sommer, Cesar
    Boldajipour, Bijan
    Valton, Julien
    Galetto, Roman
    Bentley, Trevor
    Sutton, Janette
    Ni, Yajin
    Leonard, Mark
    Van Blarcom, Thomas
    Smith, Julianne
    Chaparro-Riggers, Javier
    Sasu, Barbra
    BLOOD, 2018, 132
  • [4] Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
    Qu, Xiaoyan
    An, Gang
    Sui, Weiwei
    Wang, Tingyu
    Zhang, Xian
    Yang, Junfang
    Zhang, Yan
    Zhang, Lu
    Zhu, Judy
    Huang, Jiaqi
    Li, Jing
    Zheng, Shirley
    Zhu, Kevin
    Lan, Liping
    Chen, Shiyi
    Humphries, Michael
    Yao, Yihong
    Zhou, Daobin
    Lu, Peihua
    Qiu, Lugui
    Li, Jianyong
    BLOOD, 2021, 138 : 1830 - +
  • [5] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [6] Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
    Arora, Sankalp
    Giri, Smith
    Godby, Kelly Nicole
    Ravi, Gayathri
    Costa, Luciano J.
    Bal, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
    Zhang, Xiaohui
    Ouyang, Chenxi
    Sun, Guofeng
    Liu, Hongfeng
    Qi, Junyuan
    Suo, Xiaohui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
  • [8] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
    Yao, Xin
    Zhu, Shigui
    Huang, Jiaqi
    Qu, Xiaoyan
    Zhu, Judy
    Wei, Yutian
    Lan, Liping
    Lv, Xiaoteng
    Wu, Junfeng
    Wang, Rirfei
    Yang, Dingzhu
    Zheng, Chengxiao
    Zhao, DiJun
    Fan, Lei
    Huang, Fei
    Lu, Hua
    Zhang, Chaocan
    Chen, Cheng
    Li, Yanfeng
    Ren, Jiaqiang
    Zhang, Li
    Humphries, Michael
    Li, Jianyong
    Yao, Yihong
    BLOOD, 2019, 134
  • [9] P-BCMA-ALLO1-a nonviral, allogeneic anti-BCMA CAR-T therapy with potent antitumor function for the treatment of multiple myeloma
    Richter, Maximilian
    Cranert, Stacey
    Tan, Yening
    Tong, Min
    Domingo, Christine
    Argus, Elvira
    Ibitokou, Samad
    Smith, Jenessa
    Martin, Christopher
    Wang, Xinxin
    Barnett, Burton
    Ostertag, Eric
    Coronella, Julia
    Shedlock, Devon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
    Li, Chunrui
    Cao, Wenyue
    Que, Yimei
    Wang, Qiuxiang
    Xiao, Yi
    Gu, Chaojiang
    Wang, Di
    Wang, Jue
    Jiang, Lijun
    Xu, Hao
    Xu, Jinhuan
    Zhou, Xiaoxi
    Hong, Zhenya
    Wang, Na
    Huang, Liang
    Zhang, Shangkun
    Chen, Liting
    Mao, Xia
    Xiao, Min
    Zhang, Wei
    Meng, Li
    Cao, Yang
    Zhang, Tongcun
    Li, Jian
    Zhou, Jianfeng
    CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (03):